Myeloma is the most common plasma cell cancer in Canada, with an estimated 3317 new cases in 2019 and an estimated 1563 deaths associated with the disease.
In the past, there were fewer MM treatment options available to Canadians and resultantly many MM patients would experience poor outcomes due to resistance to therapy and a lack of alternative options/combinations.
In 2016, a new molecule was added to the armamentarium of Canadian MM treating physicians which not only has multiple, potent mechanisms of action (MoAs) but is also able to be used in combination with other therapies.
The following CARE™ Supplement highlights key trial updates and data releases in the category of MM from the 2019 American Society of Hematology (ASH) annual meeting. This CARE™ Supplement focuses on daratumumab, one of the most impactful therapies on MM management in recent years and includes content on the following:
Minimal Residual Disease (MRD)
- ASH 2019 Abstract 4742
Newly Diagnosed Multiple Myeloma (ND MM)
- The MAIA Study
- The PEGASUS Study
- The ALCYONE Study
Relapsed/Refractory Multiple Myeloma (RR MM)
- The POLLUX Study
- The CASTOR Study